Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-261-3 | CAS number: 7803-55-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Ammonium trioxovanadate is toxic via ingestion and harmful by inhalation, but not via the dermal route.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1991-12-11 to 1992-01-27
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- signed 1991-07-25
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS - Sprague-Dawley, Tif:RAI f (SPF)
- Source: Lippische Versuchstierzucht, HAGEMANN GmbH, D-4923 Extertal 1
- Age at study initiation: approximately. 40 - 60 days
- Weight at study initiation: 159 - 199 g
- Fasting period before study: feeding was discontinued approximately 16 hours before administration. Only tap water was offered ad libitum.
- Housing: granulated textured wood was used as bedding material for the cages (Granulat Typ A2, supplier: Messrs. BRANDENBURG, Inh. H. Brandenburg, D-2849 Goldenstedt). During the observation period, surviving animals were kept in groups of 2 - 3 animals in MAKROLON cages (type III).
- Diet: standardized diet for rats and mice ALTROMIN 1324 (supplied by: ALTROMIN GmbH, D-4937 Lage/Lippe)
- Water (ad libitum): tap water
- Quarantine period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22°C ± 3°C (maximum range)
- Relative humidity: 60% ± 20% (maximum range)
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.8% aqueous hydroxypropyl-methylcellulose gel
- Details on oral exposure:
- VEHICLE
- Batch no.: MM 84097413B
MAXIMUM DOSE VOLUME APPLIED: 20 mL/kg bw (dose interval factor: 2.15)
DOSAGE PREPARATION: Ammonium metavanadate was suspended in 0.8% aqueous hydroxypropyl-methylcellulose gel. - Doses:
- male and female rats: 100, 215, and 464 mg/kg bw
female rats only: 46.4 mg/kg bw - No. of animals per sex per dose:
- 5 males / 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observations were performed immediately, 5, 15, 30 and 60 minutes, as well as 3 hours, 6 hours and 24 hours after administration. During the follow-up period, changes of skin and fur, eyes and mucous membranes, respiratory and circulatory, autonomic and central nervous system and somatomotor activity as well as behaviour pattern were observed at least once a day until all symptoms subsided, and thereafter each working day. Attention was also paid to possible tremor, convulsions, salivation, diarrhoea, lethargy, sleep and coma. Observations on mortality were made at least once daily with appropriate actions taken to minimise loss of animals during the study. Individual body weights were recorded before administration of the substance, thereafter in weekly intervals up to the end of the study, and at death. Changes in weight were calculated and recorded when survival exceeds one day.
- Necropsy of survivors performed: yes; at the end of the experiments all surviving animals were sacrificed dissected and inspected macroscopically. All gross pathological changes were recorded. from animals which survived 24 hours or longer a microscopic examination of all organs which show evident lesions is performed. Autopsy and macroscopic inspection of rats which died prematurely were carried out as soon as possible after exitus. - Statistics:
- The LD50 was calculated by regression analysis and probit analysis (FINNEY). The mortality rates at 24 hours ad at 14 days were used.
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 218.1 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 after 14 days; Slope: 14.98
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 141.4 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 after 14 days; Slope: 9.32
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 169.33 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 126.86 - 226.03
- Remarks on result:
- other: LD50 after 14 days; Slope: 4.52
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 371.1 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 after 24 hours; Slope: 7.86
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 212.48 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 after 24 hours: Slope: 14.98
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 275.87 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 203.71 - 373.57
- Remarks on result:
- other: LD50 after 24 hours; Slope: 4.36
- Mortality:
- 46.4 mg/kg bw: none
100 mg/kg bw: 2 females (day 3)
215 mg/kg bw: 2 males (24 hours - day 4)/ 4 females (24 hours - day 3)
464 mg/kg bw: 5 males (4 hours - day 4) / 5 females (70 minutes - 24 hours) - Clinical signs:
- other: Male rats: 46.4 mg/kg bw: none 100 mg/kg bw: none 215 mg/kg bw: slight/moderate reduced motility (3 hours - day 2; 5 males); slight/moderate ataxia (3 hours - day 2; 5 males); slight/moderate dyspnoea (3 hours - day 2; 5 males); moderate muscular hypotoni
- Gross pathology:
- Animals that died prematurely:
215 mg/kg bw: 1/2 males and 3/4 females had reddened intestinal mucosa
464 mg/kg bw: 4/5 males had (severely) dark liver and reddened intestinal mucosa; 5/5 females had severely dark liver and (severely) reddened intestinal mucosa
All further deceased animals showed no pathological findings.
Surviving animals (sacrificed) (male and female):
no pathological findings - Interpretation of results:
- Toxicity Category III
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- LD50 (male rats) = 218.07 mg/kg bw
LD50 (female rats) = 141.43 mg/kg bw
LD50 (male and female rats) = 169.33 mg/kg bw (CL: 126.86 - 226.03 mg/kg bw)
The lowest lethal dose was 215 mg/kg bw (males) and 100 mg/kg bw (females), the no-effect level was 100 mg/kg bw (males) and 46.4 mg/kg bw (females).
According to the EC-Commission directive 67/548/EEC and its subsequent amendments, the test substance is classified as toxic if swallowed.
According to the EC-Regulation 1272/2008 and subsequent regulations, the test item is classified as Category 3.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 141.4 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1992-01-13 to 1992-02-11
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- signed 1991-07-25
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS - Sprague-Dawley/ Tif:RAI f (SPF)
- Source: Lippische Versuchstierzucht, HAGEMANN GmbH, D-4923 Extertal 1
- Age at study initiation: approximately. 40 - 60 days
- Weight at study initiation: males: 186 - 313 g; females: 175 - 215 g
- Fasting period before study: food was discontinued approximately 16 hours before exposition.
- Housing: granulated textured wood (type 2, supplied by: Johannes Brandenburg, D-2849 Goldenstedt) was used as bedding material. During the 14- day observation period, the animals were kept in groups of two or three in MAKROLON cages (type III).
- Diet (ad libitum): standardized diet for rats ALTROMIN 1324 (supplied by: ALTROMIN GmbH, D-4937 Lage/Lippe)
- Water (ad libitum): tap water
- Quarantine period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22°C ± 3°C (maximum range)
- Relative humidity: 60% ± 20% (maximum range)
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- nose only
- Vehicle:
- clean air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus/Exposure chamber volume/Method of holding animals in test chamber: the study was carried out using a dynamic inhalation apparatus with a nose only exposure of the animals according to KIMMERLE & TEPPER (RHEMA-LABORTECHNIK, D-6238 Hofheim/Taunus).
The apparatus consists of a cylindrical exposure chamber (volume 40 L) which holds a maximum of 20 animals in pyrex tubes at the edge of the chamber in a radial position.
- System of generating particulates/aerosols: the dust was generated with a dust generator and dosing apparatus (BURGHART, D-2000 Wedel/Holstein). The generator was fed with compressed air from a compressor. At the bottom of the exposure chamber the air was sucked off at a lower rate as created by the dust generator in order to produce a slight positive pressure in the exposure chamber.
- Method of particle size determination: an analysis of the particle size distribution was carried out twice during the exposure period using a cascade impactor according to MAY (1975) (MAY, K.R. 'Aerosol impaction jets', J. Aerosol Sci. 6, 403 (1975), RESEARCH ENGINEERS Ltd., (UK)-London N1 5RD).
The dust from the exposure chamber was sucked through the cascade impactor for 0.5 to 4 minutes at a constant flow rate of 5 L/min.The slides were removed from the impactor and were weighed on an analytical balance (SARTORIUS, type 1601 004, precision 10 µg).
The mass median aerodynamic diameter (MMAD) was estimated by means of nonlinear regression analysis (LITCHFIELD & WILCOXON). The 32 µm particle size range was not included in the determination of the MMAD in order not to give undue weight to this value.
- Temperature, humidity, air flow: air-flow meters (Rotameter, ROTA Apparate- und Maschinenbau, D-7867 Wehr 2/Baden) were used to control the constant supply of compressed air and vaccum. Flow rats were checked at least once/hour and corrected if necessary. Air changes per hour were 25.5.
The temperature (GTH 1200 Digital Thermometer, Fa. Greisinger Electronic GmbH, D-8413 Regenstauf) and humidity (Sekunden-Hygrometer Typ 6100, Testoterm) were continuously monitored close to the nose of the animals in the inhalation chamber. The temperature was 22°C ± 3°C and the relative humidity was 60% ± 20%.
Exposition started by locating the rats into the exposure chamber.
TEST ATMOSPHERE
- Brief description of analytical method used: the dust concentration in the inhalation chamber was measured with an air sample filter (Minisart N SM 17598; 0.45 µm) and pump (water jet air pump controlled by a rotameter). Dust samples were taken during the first half and during the second half of the exposure. Air was sucked through at the constant flow of air of 5 L/min for 1 to 4 minutes. The filters were weighed before and after sampling (accuracy 0.01 mg). Concentration of the test substance in the air was calculated as mg/L.
- Samples taken from breathing zone: yes
TEST ATMOSPHERE
- MMAD (Mass median aerodynamic diameter):
0.72 mg/L air: 7.22 µm
1.21 mg/L air: 8.21 µm
1.54 mg/L air: 10.78 µm
2.20 mg/L air: 9.94 µm
3.49 mg/L air: 13.26 µm
- Respirable amount (particle size ≤4 µm):
0.72 mg/L air: 0.19 mg/L air
1.21 mg/L air: 0.26 mg/L air
1.54 mg/L air: 0.21 mg/L air
2.20 mg/L air: 0.35 mg/L air
3.49 mg/L air: 0.36 mg/L air - Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- please refer to "Details on inhalation exposure" above
- Duration of exposure:
- 4 h
- Concentrations:
- Nominal concentration:
males and females: 1.2, 1.5, 2.5 and 3.5 mg/L air
males only: 0.7 mg/L air
Actual concentrations:
male and female rats: 1.21 ± 0.09 , 1.54 ± 0.38, 2.20 ± 0.32 and 3.49 ± 0.91 mg/L air
male rats only: 0.72 ± 0.13 mg/L air
3.49 mg/L air was the highest amount of the test substance that could be generated in the inhalation chamber. - No. of animals per sex per dose:
- 5 males / 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: during and following exposure, observations were made and recorded systematically; individual records were maintained for each animal. A careful clinical examination was made at least once each day until all symptoms subsided, thereafter each working day.
Observations on mortality were made at least once daily with appropriate actions taken to minimize loss of animals to the study, e.g. necropsy or refrigeration of those animals found dead and isolation or sacrifice of weak or moribund animals.
Individual body weights of the animals were determined before the exposure, after 1 week and at study termination.
- Necropsy of survivors performed: yes; necropsy of all animals was carried out and all gross pathological changes were recorded. From animals which survived 24 hours or longer a microscopic examination of all organs which showed evident lesions was performed. - Statistics:
- The LC50 (14 days) was calculated by regression analysis according to FINNEY.
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- 2.61 mg/L air (analytical)
- Based on:
- test mat.
- 95% CL:
- 1.69 - 4.03
- Exp. duration:
- 4 h
- Remarks on result:
- other: Slope: 3.754
- Sex:
- female
- Dose descriptor:
- LC50
- Effect level:
- 2.43 mg/L air (analytical)
- Based on:
- test mat.
- 95% CL:
- 1.82 - 3.24
- Exp. duration:
- 4 h
- Remarks on result:
- other: Slope: 5.668
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- 2.51 mg/L air (analytical)
- Based on:
- test mat.
- 95% CL:
- 1.95 - 3.23
- Exp. duration:
- 4 h
- Remarks on result:
- other: Slope: 4.479
- Sex:
- male
- Dose descriptor:
- LC0
- Effect level:
- 0.72 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Sex:
- female
- Dose descriptor:
- LC0
- Effect level:
- 1.21 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- 0.72 mg/L air: no mortality
1.21 mg/L air: one male died 6 days after start of exposure
1.54 mg/L air: one female died 24 hours after start of exposure
2.20 mg/L air: three males and 2 females died between 2 and 3 days after start of exposure
3.49 mg/L air: three males and 4 females died between 24 hours and 7 days after start of exposure. - Clinical signs:
- other: 0.72 mg/L air: no signs of systemic intolerance 1.21 mg/L air: piloerection (and lacrimation in 1 male) in 3 male animals on the first to third day of recovery 1.54 mg/L air: dyspnoea in 1 female animal on the first day of recovery 2.20 mg/L air: apathy,
- Body weight:
- No inhibition of body weight gain was observed.
- Gross pathology:
- 0.72, 1.21 and 1.54 mg/L air: no pathological findings
Animals that died prematurely:
2.20 mg/L air: 2/2 females had noses with haemorrhagic incrustation
3.49 mg/L air: 1/3 male had a nose with haemorrhagic incrustation; 2/4 females had lungs with dark-red foci
These changes can be regarded as unspecific effects which usually occur after the inhalation exposure to a dust.
All further deceased animals showed no pathological findings.
Surviving animals (sacrificed (males and females):
no pathological findings - Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- LC50 (male rats): 2.61 mg/L air (analytical)
LC50 (female rats): 2.43 mg/L air (analytical)
LC50 (male and female rats): 2.51 mg/L air (analytical)
The no-effect-level was 0.72 mg/L air for 4 hours for males and 1.21 mg/L air for females.
According to the EC-Commission directive 67/548/EEC and its subsequent amendments, the test substance is classified as harmful by inhalation.
According to the EC-Regulation 1272/2008 and subsequent regulations, the test item is classified as Category 4.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 2 430 mg/m³ air
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1992-01-14 to 1992-01-28
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- signed 1991-07-25
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS - Sprague-Dawley, Tif:RAI f (SPF)
- Source: Lippische Versuchstierzucht, HAGEMANN GmbH, D-4923 Extertal 1
- Age at study initiation: approximately. 40 - 60 days
- Weight at study initiation: 160 - 182 g
- Fasting period before study: feeding was discontinued approximately 16 hours before administration. Only tap water was offered ad libitum.
- Housing: granulated textured wood was used as bedding material for the cages (Granulat Typ A2, supplier: Messrs. BRANDENBURG, Inh. H. Brandenburg, D-2849 Goldenstedt). On the day of treatment and during the observation period, the animals were kept in groups of 2 - 3 animals in MAKROLON cages (type III).
- Diet: standardized diet for rats ALTROMIN 1324 (supplied by: ALTROMIN GmbH, D-4937 Lage/Lippe)
- Water (ad libitum): tap water
- Quarantine period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22°C ± 3°C (maximum range)
- Relative humidity: 60% ± 20% (maximum range)
- Photoperiod (hrs dark / hrs light): 12/12 - Type of coverage:
- occlusive
- Vehicle:
- other: 0.8% aqueous hydroxypropyl-methylcellulose gel
- Details on dermal exposure:
- TEST SITE
- Area of exposure: the hair on the site of application was clipped with hair-clippers without causing injury approximately 24 hours before application. The site was situated on the animal's back between the fore and hind extremities and had an area of at least 5 x 6 cm (1/10 of body surface).
- Type of wrap if used: the test substance was applied to 8 layers of gauze and then to the application site. The patch was covered with a plastic sheet and secured with adhesive plaster.
REMOVAL OF TEST SUBSTANCE
- Washing: residual substance was removed by using lukewarm tap water.
- Time after start of exposure: at the end of the exposure period
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): the volume of application was 20 mL/kg bw. The dose interval factor was 1.25.
VEHICLE
- Ammonium metavanadate was suspended in 0.8% aqueous hydroxypropyl-methylcellulose gel.
- Batch no.: MM 84097413B - Duration of exposure:
- 24 hours
- Doses:
- 2000 and 2500 mg/kg bw
- No. of animals per sex per dose:
- 5 males / 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observations were performed immediately, 5, 15, 30 and 60 minutes, as well as 3 hours, 6 hours and 24 hours after administration. During the follow-up period (at least 2 weeks) changes in skin and fur, eyes and mucous membranes, respiratory and circulatory, autonomic and central nervous system and somatomotor activity and behaviour pattern were observed at least once a day until all symptoms subsided, thereafter each working day. Attention was also paid to possible tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. Observations on mortality were made at least once daily with appropriate actions taken to minimise loss of animals during the study. Individual body weights were recorded before administration of the substance, thereafter in weekly intervals up to the end of the study, and at death. Changes in weight were calculated and recorded when survival exceeds one day.
- Necropsy of survivors performed: yes; at the end of the experiments all surviving animals were sacrificed dissected and inspected macroscopically. All gross pathological changes were recorded. From animals which survive 24 hours or longer a microscopic examination of all organs which show evident lesions was performed. Autopsy and macroscopic inspection of the animals which died prematurely were carried out as soon as possible after exitus.
- Other examinations performed: the skin was observed for the development of erythema and oedema and was rated according to the Draize scale. - Statistics:
- The LD50 could not be calculated because no mortality occurred.
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 2 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 after 24 hours and 14 days.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: LD50 after 24 hours and 14 days.
- Mortality:
- None of the animals died prematurely.
- Clinical signs:
- other: Under the present test conditions no local or systemic intolerance reactions were observed up to the highest tested dose-level of 2500 mg/kg bw by dermal administration to rats.
- Gross pathology:
- No pathological findings.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- LD50 (male rats) > 2500 mg/kg bw
LD50 (female rats) > 2500 mg/kg bw
According to the EC-Commission directive 67/548/EEC and its subsequent amendments, the test substance is not classified.
According to the EC-Regulation 1272/2008 and subsequent regulations, the test item is not classified.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 500 mg/kg bw
Additional information
reliable GLP - study performed with ammonium trioxovanadate
Justification for selection of acute toxicity – inhalation endpoint
reliable GLP - study performed with ammonium trioxovanadate
Justification for selection of acute toxicity – dermal endpoint
reliable GLP - study performed with ammonium trioxovanadate
Justification for classification or non-classification
The available information indicates that ammonium trioxovanadate is acutely toxic via the oral route and harmful via the inhalation route, but not acutely toxic or harmful via the dermal route. Ammonium trioxovanadate requires classification as toxic if swallowed (R25) and harmful by inhalation (R20) according to Directive67/548/EEC. Furthermore, ammonium trioxovanadate requires classification as toxic if swallowed (Category 3) and harmful if inhaled (Category 4) according to Regulation (EC) 1272/2008. Classification of ammonium trioxovanadate for acute toxicity via the dermal route is not required according to Directive67/548/EEC and Regulation (EC) 1272/2008.
Specific target organ toxicant (STOT) – single exposure: oral and inhalation
The classification criteria according to regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure, oral and inhalation are not met since reversible or irreversible adverse health effects (local or/and systemic) were not observed below lethal levels in addition to effects responsible for the death of the animals. Hence, classification i snot required.
Specific target organ toxicant (STOT) - single exposure: dermal
The classification criteria according to Regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure dermal are not met since adverse health effects, including reversible and irreversible, were not observed immediately or delayed after exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.